Citius Pharma Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 23

Employees

  • Stock Symbol
  • CTXR

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.50
  • (As of Friday Closing)

Citius Pharma General Information

Description

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Contact Information

Formerly Known As
TrailOne
Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Corporate Office
  • 11 Commerce Drive
  • First Floor
  • Cranford, NJ 07016
  • United States
+1 (908)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 11 Commerce Drive
  • First Floor
  • Cranford, NJ 07016
  • United States
+1 (908)

Citius Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Citius Pharma Stock Performance

As of 20-Nov-2026, Citius Pharma’s stock price is $0.50. Its current market cap is $14M with 27.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.50 $0.50 $0.37 - $1.54 $14M 27.5M 275K -$1.75

Citius Pharma Financials Summary

As of 30-Jun-2026, Citius Pharma has a trailing 12-month revenue of $7.11M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 30-Sep-2025 FY 2024 30-Sep-2024 FY 2023 30-Sep-2023
EV 20,356 19,390 73,480 76,574
Revenue 7,105 0 0 0
EBITDA (57,602) (38,311) (39,398) (32,952)
Net Income (46,274) (37,434) (39,139) (32,543)
Total Assets 142,255 130,938 116,652 103,611
Total Debt 7,177 1,813 263 481
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Citius Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Citius Pharma‘s full profile, request access.

Request a free trial

Citius Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in
Pharmaceuticals
Cranford, NJ
23 As of 2025

Rahway, NJ
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Citius Pharma Competitors (50)

One of Citius Pharma’s 50 competitors is Merck & Co., a Corporation company based in Rahway, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Rahway, NJ
Roivant Sciences Formerly PE-Backed New York, NY
Kodiak Sciences Formerly VC-backed Palo Alto, CA
Gilead Formerly VC-backed Foster City, CA
Cynata Therapeutics Corporation Cremorne, Australia
You’re viewing 5 of 50 competitors. Get the full list »

Citius Pharma Patents

Citius Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240358716-A1 Halobetasol propionate-lidocaine formulations Pending 27-Apr-2023
US-20260174783-A1 Halobetasol propionate-lidocaine formulations Pending 27-Apr-2023
WO-2024227098-A1 Halobetasol propionate-lidocaine formulations Inactive 27-Apr-2023
US-20240358321-A1 Methods and systems for assessing hemorrhoids and treatment effectiveness thereof Pending 27-Apr-2023
WO-2024227106-A1 Methods and systems for assessing hemorrhoids and treatment effectiveness thereof Inactive 27-Apr-2023 G16H50/20
To view Citius Pharma’s complete patent history, request access »

Citius Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Citius Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Citius Pharma‘s full profile, request access.

Request a free trial

Citius Pharma Investments & Acquisitions (3)

Citius Pharma’s most recent deal was a Corporate Asset Purchase with Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) for . The deal was made on 07-Sep-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) 07-Sep-2021 Corporate Asset Purchase Buildings and Property
Leonard-Meron Biosciences 04-Apr-2016 Merger/Acquisition Drug Discovery
Trail One 12-Sep-2014 Merger/Acquisition Automotive
To view Citius Pharma’s complete investments and acquisitions history, request access »

Citius Pharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.71 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Citius Pharma’s complete esg history, request access »

Citius Pharma FAQs

  • When was Citius Pharma founded?

    Citius Pharma was founded in 2007.

  • Where is Citius Pharma headquartered?

    Citius Pharma is headquartered in Cranford, NJ.

  • What is the size of Citius Pharma?

    Citius Pharma has 23 total employees.

  • What industry is Citius Pharma in?

    Citius Pharma’s primary industry is Pharmaceuticals.

  • Is Citius Pharma a private or public company?

    Citius Pharma is a Public company.

  • What is Citius Pharma’s stock symbol?

    The ticker symbol for Citius Pharma is CTXR.

  • What is the current stock price of Citius Pharma?

    As of 20-Nov-2026 the stock price of Citius Pharma is $0.50.

  • What is the current market cap of Citius Pharma?

    The current market capitalization of Citius Pharma is $14M.

  • What is Citius Pharma’s current revenue?

    The trailing twelve month revenue for Citius Pharma is $7.11M.

  • Who are Citius Pharma’s competitors?

    Merck & Co., Roivant Sciences, Kodiak Sciences, Gilead, and Cynata Therapeutics are some of the 50 competitors of Citius Pharma.

  • What is Citius Pharma’s annual earnings per share (EPS)?

    Citius Pharma’s EPS for 12 months was -$1.75.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process